FibroBiologics Files 2024 First Quarter Report
15 May 2024 - 7:24AM
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
clinical-stage biotechnology company with 150+ patents issued and
pending for the development of therapeutics and potential cures for
chronic diseases using fibroblasts and fibroblast-derived
materials, has filed its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2024, with the U.S. Securities and Exchange
Commission.
The filing can be viewed through a link on
FibroBiologics’ website at
https://ir.fibrobiologics.com/sec-filings/quarterly-reports.
About FibroBiologics Based
in Houston, FibroBiologics is a cell therapy, regenerative medicine
company developing a pipeline of treatments and potential cures for
chronic diseases using fibroblast cells and fibroblast-derived
materials. FibroBiologics holds 150+ US and internationally issued
patents/patents pending across various clinical pathways, including
disc degeneration, orthopedics, multiple sclerosis, psoriasis,
wound healing, reversing organ involution, and cancer.
FibroBiologics represents the next generation of medical
advancement in cell therapy. For more information, visit
www.FibroBiologics.com.
General
Inquiries:info@fibrobiologics.com
Investor Relations:Nic Johnson Russo
Partners212-845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347)
956-7697Elizabeth.phillips@russopartnersllc.com
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Aug 2024 to Sep 2024
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Sep 2023 to Sep 2024